AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6352304 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dosed beta-2-agonists (1/4 mg terbutaline)
Number of subjects: 10
Study 30650256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GSK1940029 (0.3% and 1%, occluded application)
Number of subjects: 93
Study 30650256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GSK1940029 (0.1% to 1%, single and repeat doses, occluded and nonoccluded applications)
Number of subjects: 93
Study 30650256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GSK1940029 (0.1% to 1%, occluded application)
Number of subjects: 93
Study 28818853 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping
Number of subjects: 40
Study 28818853 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 40
Study 28818853 — intervention group
Group type: EXPERIMENTAL
Intervention: SVC flow measurements
Number of subjects: 40
Study 28818853 — intervention group
Group type: EXPERIMENTAL
Intervention: RVO measurements
Number of subjects: 40
Study 28818853 — intervention group
Group type: EXPERIMENTAL
Intervention: DA diameter measurements
Number of subjects: 40
Study 26812304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence
Number of subjects: 134
Study 26812304 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners of females with stress urinary incontinence
Number of subjects: 134
Study 26812304 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with stress urinary incontinence
Number of subjects: 134
Study 26812304 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with stress urinary incontinence
Number of subjects: 134
Study 24074649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive MI (9 sessions)
Number of subjects: 163
Study 24074649 — intervention group
Group type: COMPARATOR
Intervention: Standard MI (1 session)
Number of subjects: 163
Study 22391083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine artery ligation
Number of subjects: 30
Study 22391083 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic inferior turbinoplasty without sphenopalatine artery ligation
Number of subjects: 30
Study 20628884 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise (DE) group
Number of subjects: 19
Study 20628884 — intervention group
Group type: COMPARATOR
Intervention: Diet (D) group
Number of subjects: 19
Study 17222278 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized assessment-feedback on male and female population drinking norms by mail
Number of subjects: 1727
Study 17222278 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 1727
Study 15822121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap interval of 8-30 days
Number of subjects: 5055
Study 15822121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap interval of 121-184 days
Number of subjects: 5055
Study 15822121 — intervention group
Group type: COMPARATOR
Intervention: CIN3 group
Number of subjects: 5055
Study 12062912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 12062912 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 51
Study 12062912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10218659 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated Ensure (Re‐En)
Number of subjects: 32
Study 10218659 — intervention group
Group type: COMPARATOR
Intervention: Standard Ensure (En)
Number of subjects: 32
Study 10218659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Re‐En and En
Number of subjects: 32
Study 8829954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs and diet (2 to 3 years)
Number of subjects: 1240
Study 8829954 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle changes (stress management, intensive exercise, low fat diet) (1 to 3 years)
Number of subjects: 1240
Study 8829954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1240
Study 2090478 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline with manufacturer's insert (Group A)
Number of subjects: 40
Study 2090478 — intervention group
Group type: COMPARATOR
Intervention: Theophylline without manufacturer's insert (Group B)
Number of subjects: 40
Study 2090478 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (both groups)
Number of subjects: 40
Study 346140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk forming agent (ispaghula husk)
Number of subjects: 53
Study 346140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30543570 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nursing interventions informed by the Health Belief Model
Number of subjects: 61
Study 30543570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 31345179 — intervention group
Group type: EXPERIMENTAL
Intervention: APAD intervention (thrice-weekly moderate-intensity mixed aerobic and resistance exercise sessions and 9 dietetic consultations)
Number of subjects: 143
Study 31345179 — intervention group
Group type: EXPERIMENTAL
Intervention: APAD intervention
Number of subjects: 143
Study 31345179 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 143
Study 29059644 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol at a dose of 100 mg per os daily added to standard therapy
Number of subjects: 85
Study 29059644 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Β‐blockers, statins, aspirin)
Number of subjects: 85
Study 25231029 — intervention group
Group type: COMPARATOR
Intervention: SLA implants
Number of subjects: 20
Study 25231029 — intervention group
Group type: COMPARATOR
Intervention: SLActive implants
Number of subjects: 20
Study 24325653 — intervention group
Group type: EXPERIMENTAL
Intervention: Doktor Muda Programme (DMP)
Number of subjects: 3455
Study 24325653 — intervention group
Group type: COMPARATOR
Intervention: Non-DMP (control)
Number of subjects: 3455
Study 21840840 — intervention group
Group type: EXPERIMENTAL
Intervention: TCARE® intervention
Number of subjects: 266
Study 21840840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266
Study 19892299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 19892299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 19892299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 19892299 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 53048
Number of subjects: 0
Study 19892299 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban (S18886)
Number of subjects: 0
Study 16399214 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone (GHRH)
Number of subjects: 89
Study 15513305 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based antihypertensive therapy
Number of subjects: 42
Study 11757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate treatment (1 mg folic acid, 400 microg vitamin B12, 10 mg pyridoxine)
Number of subjects: 205
Study 11757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate treatment
Number of subjects: 205
Study 11757505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 9056055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 10
Study 9056055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8373297 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-modified amalgam
Number of subjects: 59
Study 8373297 — intervention group
Group type: EXPERIMENTAL
Intervention: Palladium-modified amalgam
Number of subjects: 59
Study 8373297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersed phase amalgam
Number of subjects: 59
Study 8373297 — intervention group
Group type: EXPERIMENTAL
Intervention: All three alloys
Number of subjects: 59
Study 8373297 — intervention group
Group type: COMPARATOR
Intervention: Static creep
Number of subjects: 59
Study 3003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (10 mg/kg) administered intravenously at 8-hr intervals for seven days
Number of subjects: 31
Study 3003206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (10 mg/kg)
Number of subjects: 31
Study 31330457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-injection paravertebral block (PVB)
Number of subjects: 72
Study 31330457 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection erector spinae plane block (ESPB)
Number of subjects: 72
Study 31330457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intercostal nerve block (ICNB)
Number of subjects: 72
Study 29291958 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 100+ sunscreen
Number of subjects: 199
Study 29291958 — intervention group
Group type: COMPARATOR
Intervention: SPF 50+ sunscreen
Number of subjects: 199
Study 26882453 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (TXT) + Tamoxifen (TAM)
Number of subjects: 120
Study 26882453 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (TXT)
Number of subjects: 120
Study 23563752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (n = 70)
Number of subjects: 247
Study 23563752 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 65)
Number of subjects: 247
Study 22402710 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-ankle orthosis (AABA)
Number of subjects: 0
Study 22402710 — intervention group
Group type: COMPARATOR
Intervention: Below-ankle orthosis (BA)
Number of subjects: 0
Study 21077581 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0
Study 21077581 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 18996235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushrim-activated power-assisted wheelchairs (PAPAWs)
Number of subjects: 18
Study 18996235 — intervention group
Group type: COMPARATOR
Intervention: Manual wheelchair propulsion
Number of subjects: 18
Study 15966878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic root debridement on the second molar followed by a three‐visit plaque control programme
Number of subjects: 30
Study 15966878 — intervention group
Group type: COMPARATOR
Intervention: Standard socket debridement
Number of subjects: 30
Study 12069217 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring intervention
Number of subjects: 0
Study 12069217 — intervention group
Group type: COMPARATOR
Intervention: Control dyads
Number of subjects: 0
Study 10073741 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (2 x 200 mg day(‐1) p.o.)
Number of subjects: 10
Study 10073741 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol (2 x 200 mg day(‐1) p.o.) after 2 weeks
Number of subjects: 10
Study 10073741 — intervention group
Group type: COMPARATOR
Intervention: ketotifen (2 x 1 mg day(‐1) p.o.)
Number of subjects: 10
Study 7668851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Up On Arthritis (BUOA) intervention delivered by community-based service organization
Number of subjects: 154
Study 2209920 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen
Number of subjects: 77
Study 2209920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2209920 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.3%
Number of subjects: 77
Study 7030976 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (500 mg orally three times daily) + Salbutamol (3 mg p.o.)
Number of subjects: 0
Study 7030976 — intervention group
Group type: COMPARATOR
Intervention: Proxyphylline (500 mg orally three times daily) + Placebo
Number of subjects: 0
Study 6387888 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50-100 mg twice daily)
Number of subjects: 52
Study 6387888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31994510 — intervention group
Group type: EXPERIMENTAL
Intervention: Migrepam (zolmitriptan) 2.5 mg
Number of subjects: 60
Study 31994510 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 60
Study 29927666 — intervention group
Group type: EXPERIMENTAL
Intervention: BikeSafe on-bicycle curriculum (intervention group)
Number of subjects: 286
Study 29927666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 286
Study 26785820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg daily for 4 weeks)
Number of subjects: 22
Study 26785820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25391155 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 64
Study 25391155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22682883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding route
Number of subjects: 101
Study 22682883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoduodenal (ND) feeding route
Number of subjects: 101
Study 20605484 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG)
Number of subjects: 35
Study 20605484 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard surgical treatment without APG)
Number of subjects: 35
Study 18593741 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol/week for 9 months
Number of subjects: 64
Study 18593741 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol/month during maintenance phase
Number of subjects: 64
Study 18593741 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no cholecalciferol) during maintenance phase
Number of subjects: 64
Study 15957842 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 30 mg daily
Number of subjects: 140
Study 15957842 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 20 mg daily
Number of subjects: 140
Study 15957842 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 10 mg daily
Number of subjects: 140
Study 15957842 — intervention group
Group type: COMPARATOR
Intervention: Control group (only medicated with JBG)
Number of subjects: 140
Study 11846197 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMP) with simplified papilla preservation (SPP) technique
Number of subjects: 90
Study 11846197 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-reinforced ePTFE membranes with SPP technique
Number of subjects: 90
Study 11846197 — intervention group
Group type: COMPARATOR
Intervention: Access flap control procedure (SPP technique)
Number of subjects: 90
Study 10091737 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy (6 courses)
Number of subjects: 39
Study 10091737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systemic adjuvant treatment)
Number of subjects: 39
Study 7751496 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-biofeedback training with propranolol (60, 120, or 180 mg/day)
Number of subjects: 33
Study 7751496 — intervention group
Group type: COMPARATOR
Intervention: Relaxation-biofeedback training alone
Number of subjects: 33
Study 7751496 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-biofeedback training with propranolol
Number of subjects: 33
Study 2311595 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer drink containing electrolytes (GP; 7% CHO, 231 mosmol.kg‐1)
Number of subjects: 9
Study 2311595 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte placebo drink without carbohydrate (EP; 48 mosmol.kg‐1)
Number of subjects: 9
Study 2311595 — intervention group
Group type: COMPARATOR
Intervention: Non‐electrolyte placebo (NEP; 31 mosmol.kg‐1)
Number of subjects: 9
Study 6765502 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 10
Study 6765502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31648072 — intervention group
Group type: COMPARATOR
Intervention: Filtered air control
Number of subjects: 48
Study 31648072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookstove treatments
Number of subjects: 48
Study 31171031 — intervention group
Group type: EXPERIMENTAL
Intervention: early patient-directed rehabilitation
Number of subjects: 76
Study 31171031 — intervention group
Group type: COMPARATOR
Intervention: standard rehabilitation incorporating sling immobilisation
Number of subjects: 76
Study 30057406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m2
Number of subjects: 126
Study 30057406 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 900 mg/m2 and docetaxel 75 mg/m2
Number of subjects: 126
Study 27502725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus second-line chemotherapy
Number of subjects: 494
Study 27502725 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 494
Study 23959095 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (500μg) and clonidine (75μg)
Number of subjects: 100
Study 23959095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 100
Study 21997458 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic weightlifting (OL) training
Number of subjects: 26
Study 21997458 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weight (TW) training
Number of subjects: 26
Study 21997458 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 26
Study 19151995 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD
Number of subjects: 212
Study 19151995 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 212
Study 18063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 6 mg/m2 and standard-dose cytarabine 100 mg/m2
Number of subjects: 0
Study 18063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 with standard- and high-dose cytarabine and anthracyclines
Number of subjects: 0
Study 18063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 and high-dose cytarabine 3 g/m2
Number of subjects: 0
Study 18063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 0
Study 18063879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) within a reduced-intensity conditioning protocol applying fludarabine and total body irradiation
Number of subjects: 0
Study 15189542 — intervention group
Group type: EXPERIMENTAL
Intervention: Double marker-guided venipuncture of extrathoracic subclavian and/or axillary vein
Number of subjects: 0
Study 11742463 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene liner THA
Number of subjects: 150
Study 11742463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal liner THA
Number of subjects: 150
Study 9509824 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 16
Study 9509824 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 16
Study 9509824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 8214926 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms)
Number of subjects: 16
Study 8214926 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3301417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical artificial insemination (IC‐AIH)
Number of subjects: 20
Study 3301417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine artificial insemination (IU‐AIH)
Number of subjects: 20
Study 3301417 — intervention group
Group type: COMPARATOR
Intervention: Timed vaginal intercourse
Number of subjects: 20
Study 30361792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide 600 mg twice daily for 60 days
Number of subjects: 29
Study 30361792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27886729 — intervention group
Group type: EXPERIMENTAL
Intervention: Social capital intervention
Number of subjects: 52
Study 25503265 — intervention group
Group type: EXPERIMENTAL
Intervention: Active arm (FTC/Tenofovir)
Number of subjects: 0
Study 25503265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23841295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 23841295 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and Fentanyl
Number of subjects: 40
Study 20214687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous partial pressure of carbon dioxide (PtCO(2)) device
Number of subjects: 24
Study 20214687 — intervention group
Group type: COMPARATOR
Intervention: Arterial blood gas
Number of subjects: 24
Study 18765504 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1-month time window)
Number of subjects: 4028
Study 18765504 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1 to 3 prescriptions in the previous year)
Number of subjects: 4028
Study 18765504 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin exposure (1-year time window using case-time-control approach)
Number of subjects: 4028
Study 16443871 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (depression collaborative care program)
Number of subjects: 418
Study 14752343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar (epsilon aminocaproic acid)
Number of subjects: 36
Study 14752343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Amicar)
Number of subjects: 36
Study 11391748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amantadine (200 mg)
Number of subjects: 9
Study 11391748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8607888 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral pamidronate/day
Number of subjects: 105
Study 8607888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105